Amartya kumar,
- Student, Department of Biotechnology, Dronacharya groups of institutions,Greater Noida, Uttar Pradesh, India
Abstract
Cardiovascular diseases (CVDs) are the leading cause of death globally, with complex etiologies involving genetic, environmental, and lifestyle factors. Genome-wide association studies (GWAS) have significantly advanced the understanding of genetic underpinnings of CVDs by identifying numerous risk loci and variants associated with various cardiovascular conditions. This review explores the potential of GWAS to drive precision medicine in cardiovascular diseases by linking genetic data with clinical outcomes, providing insights into disease pathogenesis, and enabling the development of personalized therapeutic strategies. Although GWAS has provided extensive insights, challenges persist in applying these discoveries to clinical practice due to the intricate interplay between genes and the environment, as well as the multifaceted polygenic nature of CVDs. The review also highlights the importance of integrating GWAS data with other omics technologies, including transcriptomics and proteomics, to provide a more comprehensive understanding of cardiovascular health and disease. Finally, we discuss the need for diverse population representation in GWAS, emphasizing the importance of reducing health disparities through the inclusion of underrepresented ethnic groups. The future of precision medicine in CVDs relies on overcoming current challenges, incorporating multi-omics approaches, and ensuring equity in genomic research.
Keywords: Cardiovascular diseases (CVDs), genome-wide association studies (GWAS), genetic underpinnings, risk loci, clinical outcomes, disease pathogenesis, precision medicine, personalized therapeutic strategies, gene-environment interactions, polygenic nature
[This article belongs to Research and Reviews : Journal of Computational Biology ]
Amartya kumar. Leveraging Genome-Wide Association Studies for Precision Medicine in Cardiovascular Diseases. Research and Reviews : Journal of Computational Biology. 2025; 14(01):35-39.
Amartya kumar. Leveraging Genome-Wide Association Studies for Precision Medicine in Cardiovascular Diseases. Research and Reviews : Journal of Computational Biology. 2025; 14(01):35-39. Available from: https://journals.stmjournals.com/rrjocb/article=2025/view=194706
References
1. Cho SMJ, Koyama S, Honigberg MC, Surakka I, Haidermota S, Ganesh S, et al. Genetic, sociodemographic, lifestyle, and clinical risk factors of recurrent coronary artery disease events: a population-based cohort study. Eur Heart J. 2023;44(36):3456–3465. doi:10.1093/eurheartj/ehad380.
2. Harismendy O, Notani D, Song X, Rahim NG, Tanasa B, Heintzman N, et al. 9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response. Nature. 2011;470(7333):264–268. doi:10.1038/nature09753.
3. The CARDIoGRAMplusC4D Consortium. A comprehensive 1000 genomes–based genome-wide association meta-analysis of coronary artery disease. Nat Genet. 2015;47(10):1121–1130. doi:10.1038/ng.3396.
4. Low SK, Takahashi A, Ebana Y, Ozaki K, Christophersen IE, Ellinor PT, et al. Identification of six new genetic loci associated with atrial fibrillation in the Japanese population. Nat Genet. 2017;49(6):953–958. doi:10.1038/ng.3842.
5. McPherson R, Tybjaerg-Hansen A. Genetics of coronary artery disease. Circul Res. 2016;118(4):564–578. doi:10.1161/circresaha.115.306566.
6. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219–1224. doi:10.1038/s41588-018-0183-z.
7. Hartiala J, Schwartzman WS, Gabbay J, Ghazalpour A, Bennett BJ, Allayee H. The genetic architecture of coronary artery disease: Current knowledge and future opportunities. Curr Atheroscler Rep. 2017;19(2):6. doi:10.1007/s11883-017-0641-6.
8. Abramowitz Y, Roth A, Keren G, Isakov O, Shomron N, Laitman Y, et al. Whole-exome sequencing in individuals with multiple cardiovascular risk factors and normal coronary arteries. Coron Artery Dis. 2016;27(4):257–266. doi:10.1097/MCA.0000000000000357.
9. Sethi Y, Patel N, Kaka N, Kaiwan O, Kar J, Moinuddin A, et al. Precision medicine and the future of cardiovascular diseases: A clinically oriented comprehensive review. J Clin Med. 2023;12(5):1799. doi:10.3390/jcm12051799.
10. Li C, Pan Y, Zhang R, Huang Z, Li D, Han Y, et al. Genomic innovation in early life cardiovascular disease prevention and treatment. Circul Res. 2023;132(12):1628–1647. doi:10.1161/CIRCRESAHA.123.321999.
11. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, et al. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316(5830):1488–1491. doi:10.1126/science.1142447.
12. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. Deriving the consequences of genomic variants with the Ensembl API and SNP effect predictor. Bioinform. 2010;26(16):2069–2070. doi:10.1093/bioinformatics/btq330.
13. Harrison PW, Amode MR, Austine-Orimoloye O, Azov AG, Barba M, Barnes I, et al. Ensembl 2024. Nucleic Acids Res. 2024;52(D1):D891–D899. doi:10.1093/nar/gkad1049.
14. Curwen V, Eyras E, Andrews TD, Clarke L, Mongin E, Searle SM, et al. The Ensembl automatic gene annotation system. Genome Res. 2004;14(5):942–950. doi:10.1101/gr.1858004.
15. Chen Y, Cunningham F, Rios D, McLaren WM, Smith J, Pritchard B, et al. Ensembl variation resources. BMC Genomics. 2010;11:1–6.
16. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, et al. The Ensembl variant effect predictor. Genome Biol. 2016;17:1–4.
17. Cunningham F, Allen JE, Allen J, Alvarez-Jarreta J, Amode MR, Armean IM, et al. Ensembl 2022. Nucleic Acids Res. 2022;50(D1):D988–D995. doi:10.1093/nar/gkab1049.
Research and Reviews : Journal of Computational Biology
| Volume | 14 |
| Issue | 01 |
| Received | 24/12/2024 |
| Accepted | 16/01/2025 |
| Published | 20/01/2025 |
| Publication Time | 27 Days |
Login
PlumX Metrics